NERV - Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that is in Phase IIb clinical trial. Its products in Phase IIa clinical trial comprise MIN-117, a compound for the treatment of patients suffering from major depressive disorder; and MIN-202, a selective orexin 2 receptor antagonist for the treatment of primary and comorbid insomnia. The company' preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease. It has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

 

Minerva Neurosciences Inc (NERV) Shares Skyrocket Following Successful Schizophrenia Drug Trial

Shares of Minerva Neurosciences Inc (NASDAQ:NERV) have surged by more than 235% today after the company announced positive results from the Phase IIb trial of its antidepressant drug candidate MIN-101. Results from the study proved the superiority of MIN-101 compared to a placebo in its primary endpoint of improving negative symptoms, which is judged using the pentagonal structure model (PSM) of the Positive and Negative Syndrome Scale (PANSS). The treatment also effectively met several secondary endpoints. In a statement, Minerva’s CEO Dr. Remy Luthringer said that the results depict the meaningful benefit of the drug and support its further development. Dr. Luthringer said that the company’s drug has the potential to address the currently unmet medical needs in the treatment of mood disorders and other central nervous system problems, which are not addressed by existing therapies.

http://www.insidermonkey.com/blog/m...g-successful-schizophrenia-drug-trial-456147/

 

This must have been a crazy ride for long term holders!

Last week this cascaded down as if it was the end of the world, then you wake up today to see a +250% move!

 

The next one?

Dont we just short the current ones?

 

https://www.thestreet.com/story/13587382/2/biotech-stock-mailbag-sage-therapeutics-minerva.html
By Adam Feuerstein ‏@adamfeuerstein

I confess to not knowing anything about Minerva Neurosciences (NERV) before Thursday when the stock soared 265% on the announced results from the MN-101 phase II study in schizophrenia. I don't know if these data are real or not, meaning if the efficacy of MN-101 can be confirmed when Minerva eventually runs larger studies.

I'm not helpful. Apologies. But take a look at the Minerva chart. It's a case study for why investors love biotech. You don't see stock charts like this in any other industry.



Back in March, I wrote a column about how to spot red flags in clinical trial data. Minerva's press release on Thursday trips some of those red flags. The phase II study was conducted mostly in Russia and Eastern Europe. Minerva disclosed the treatment effect sizes for MN-101 compared to placebo (the statistical measure) but the company did not provide baseline characteristics for patients or the actual numeric changes in the schizophrenia ratings scale over the course of the study.

Two patients discontinued from the study due to QTc prolongations (irregular heart rhythms). Minerva did not hold a conference call to discuss the study results so that investors and analysts could ask questions and get more details.

MN-101 could be the real thing. The Minerva study was randomized, double-blinded and used a placebo control. I'm just saying getting more detailed data from the MN-101 schizophrenia study is a good idea, particularly with the stock's extreme reaction. The CNS treatment landscape is littered with the corpses of drugs that looked awesome in small, phase II studies but then blew up in larger, phase III studies.

It's so much easier when you own these small-cap biotech stocks before they rocket higher.

 

Nice pop here but possible short term shorting opportunity

 

Anybody buying?

 

Well, will you look at that action today!